Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
118 hedge funds and large institutions have $606M invested in Infinity Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 9 closing their positions.
222% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 9
20% more funds holding
Funds holding: 98 → 118 (+20)
1% more capital invested
Capital invested by funds: $598M → $606M (+$7.53M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
28% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 40
47% less call options, than puts
Call options by funds: $12.9M | Put options by funds: $24.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$9.71M |
| 2 |
Millennium Management
New York
|
+$8.79M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$5.57M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.8M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.2M |
| 3 |
BC
Broadfin Capital
New York
|
-$6.96M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$5.68M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$4.09M |
INFI Hedge Fund Activity: Q3 2014 in Review
118 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2014, worth a combined $606M — up 1.3% from $598M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new INFI positions and 9 closed out — a net gain of 20 holders — while 29 added to existing stakes and 40 trimmed.
The largest buyer was BB Biotech, adding an estimated $9.71M. The largest seller was Point72 Asset Management, cutting an estimated $20.4M.
- 118 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2014, up from 98 in Q2 2014.
- Funds reported $606M of Infinity Pharmaceuticals, Inc. stock for Q3 2014, up 1.3% quarter-over-quarter.
- 29 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2014 and 9 closed out, a net change of +20 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2014 was BB Biotech, an estimated $9.71M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q3 2014 was Point72 Asset Management, an estimated $20.4M sold.
Based on aggregated 13F filings for Q3 2014.